Context.—: Endocervical adenocarcinoma is divided into human papillomavirus (HPV)-associated (HPVA) and HPV-independent (HPVI) in the 5th edition of the World Health Organization (WHO) tumor classification launched in 2020. However, the validity of the morphologic criteria used for biopsy specimens in real-world practice remains undetermined.
Objective.—: To validate the utility of the 5th edition of the WHO classification for biopsy samples, focusing on its diagnostic criteria with the aid of ancillary studies.
Design.—: We retrieved 217 cases of endocervical adenocarcinoma from 6 institutions, in which glass slides of both biopsy and resection specimens were available for review. Concordance between the biopsy and resection specimen diagnoses was evaluated. For discordant diagnoses, an algorithmic approach with ancillary studies proposed by the international group was applied to confirm their utility to improve the accuracy of biopsy diagnosis.
Results.—: The biopsy diagnosis matched the resection specimen diagnosis in 197 cases (concordance rate, 91%; κ = 0.75). The concordance rate was significantly higher for HPVA than HPVI (95% versus 81%, P = .001). There were no significant differences in the proportions of HPVA and HPVI or the accuracy of biopsy diagnosis between the participating institutions. All 19 discordant cases with unstained glass slides available were accurately recategorized as HPVA or HPVI using HPV in situ hybridization; p16 immunohistochemistry was positive in 3 of 9 cases of gastric-type HPVI that were negative by in situ hybridization.
Conclusions.—: The 5th edition of the WHO criteria for biopsy diagnosis of endocervical adenocarcinoma distinguishes HPVA from HPVI well when ancillary studies are adequately applied.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5858/arpa.2023-0360-OA | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Subtypes of Vulvar Squamous Cell Carcinoma: The Significance of HPV-Independent/p53 Wild Type.
Cancers (Basel)
December 2024
Division of Gynecologic, Breast and Perinatal Pathology, Institute of Pathology, University Hospital Leipzig, D-04103 Leipzig, Germany.
Vulvar carcinoma is a rare disease, meeting the criteria for a "rare cancer", but its incidence is increasing, especially in women <60 years of age. Squamous cell carcinoma (VSCC) accounts for the overwhelming majority of vulvar carcinomas and is the focus of this review. As with many cancers, the increased understanding of molecular events during tumorigenesis has led to the emergence of the molecular subclassification of VSCC, which is subclassified into tumors that arise secondary to high-risk human papillomavirus infection (HPV-associated, or HPVa) and those that arise independently of HPV (HPVi), most commonly in the setting of a chronic inflammatory condition of the vulvar skin.
View Article and Find Full Text PDFEndocervical adenocarcinoma with a micropapillary component: a clinicopathologic analysis in the setting of current WHO classification.
Virchows Arch
November 2024
Department of Surgical Pathology, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, School of Medicine, Women's Hospital, Zhejiang University, Hangzhou, Zhejiang Province, China.
Article Synopsis
- The study analyzed 26 cases of endocervical adenocarcinoma with a micropapillary component (EAC-MP) among 511 adenocarcinomas to explore their clinicopathologic and molecular characteristics.
- HPV-associated micropapillary adenocarcinomas (HPVA-MP) exhibited worse clinical features including larger tumor size, higher rates of lymphovascular invasion, and poorer survival outcomes compared to those without the micropapillary component (HPVA-NMP).
- The study identified significant gene mutations and HER2 amplification in EAC-MP, suggesting potential for targeted therapies and emphasizing the micropapillary structure as a marker for unfavorable outcomes in patients.
Simultaneous p53 and p16 Immunostaining for Molecular Subclassification of Head and Neck Squamous Cell Carcinomas.
Head Neck Pathol
August 2024
Department of Pathology, University of Turku, Turku University Hospital, D5020, Medisiina D, 5. floor Kiinamyllynkatu 10, Turku, FIN-20520, Finland.
Article Synopsis
- The study aimed to evaluate the effectiveness of simultaneous staining for p16 and p53 proteins in categorizing head and neck squamous cell carcinomas (HNSCC) as either HPV-associated or HPV-independent.
- Researchers stained 31 HNSCC samples for p16 and p53, and used advanced sequencing methods to analyze mutations and HPV presence in some cases.
- Results showed that most tumors (28 out of 31) could be classified simply based on the staining patterns, with most HPV-A tumors having p16 positivity and wildtype p53, while HPV-I tumors showed p16 negativity and abnormal p53 patterns.
Whole-Exome Sequencing of Vulvar Squamous Cell Carcinomas Reveals an Impaired Prognosis in Patients With TP53 Mutations and Concurrent CCND1 Gains.
Mod Pathol
October 2024
Facultat de Medicina i Ciències de la Salut, Department de Fonaments Clinics, Universitat de Barcelona, Barcelona, Spain; Barcelona Institute of Global Health (ISGlobal)-University of Barcelona, Barcelona, Spain; Department of Pathology, Hospital Clínic of Barcelona-University of Barcelona, Barcelona, Spain. Electronic address:
Article Synopsis
- Scientists don't know much about vulvar squamous cell carcinoma (VSCC), a cancer mostly found in older women, especially about its mutations and how different types affect survival.
- In a study of 60 patients, they found three main types of VSCC related to the human papillomavirus (HPV) and some common gene mutations, particularly in the TP53 gene.
- Patients with mutations in TP53 and CCND1 had a much higher chance of their cancer coming back, suggesting that these changes could help doctors find better treatments for VSCC.
Retrospective analysis of cytology and high-risk HPV testing in 1067 endocervical adenocarcinomas and precursor lesions.
Cancer Cytopathol
June 2024
Department of Surgical Pathology and Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Zhejiang Provincial Clinical Research Center for Obstetrics and Gynecology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Background: Cytology and high-risk human papilloma virus (hrHPV) cotesting is the mainstay in the detection of cervical carcinoma.
Methods: Endocervical adenocarcinoma (EAC) is divided into HPV-associated adenocarcinoma (HPVA) and HPV-independent adenocarcinoma (HPVI) by the World Health Organization classification (2020). The detection effect of cotesting is suggested to be different among EAC subtypes and precursors, but has not well-documented yet.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!